




The relative strengths and weaknesses of Summit Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Summit Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Summit Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is 218%, being 12% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	720,301
Cost of Goods Sold	0
Intangible Assets	2,001
Liabilities, Current	72,988
Liabilities, Non-Current	19,334
Other Assets	27,821
Other Compr. Net Income	-255
Other Expenses	0
Other Liabilities	0
Other Net Income	14,838
Other Revenues	0
Property and Equipment	1,059
Research and Development	537,674
Selling, General and Administrative Expense	556,750

Output Variable	Value in 1000 USD
Assets	751,182
Liabilities	92,322
Expenses	1,094,424
Revenues	0
Stockholders Equity	658,860
Net Income	-1,079,586
Comprehensive Net Income	-1,079,714
BaseVar	976,510
ECR before Limited Liability	85%
Economic Capital Ratio	218%